1. Search Result
Search Result
Results for "

10A

" in MedChemExpress (MCE) Product Catalog:

106

Inhibitors & Agonists

1

Peptides

5

Inhibitory Antibodies

2

Natural
Products

19

Recombinant Proteins

3

Isotope-Labeled Compounds

24

Antibodies

38

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-R00059

    MicroRNA Cancer
    hsa-miR-10a-5p mimics are small, chemically synthesized double-stranded RNAs that mimic endogenous miRNAs and enable miRNA functional analysis by up-regulation of miRNA activity.
    hsa-miR-10a-5p mimic
    hsa-miR-10a-5p mimic
  • HY-W116007

    Environmental Pollutants DNA/RNA Synthesis Endocrinology
    Octamethylcyclotetrasiloxane promotes the anchorage-independent growth of MCF-10A and MCF-10F cells. Octamethylcyclotetrasiloxane induces DNA damage, inhibits the expression of DNA-repairing protein BRCA1 under long-term and high-concentration exposure. Octamethylcyclotetrasiloxane exhibits intrinsic estrogenic activity .
    Octamethylcyclotetrasiloxane
  • HY-144666

    Glutaminase Cancer
    GLS-1-IN-1 (compound 1d) is a GLS-1 inhibitor. GLS-1-IN-1 shows inhibitory effect against Hep G2, MCF 7, and MCF 10A cells .
    GLS-1-IN-1
  • HY-147028

    mAChR Neurological Disease
    M4 mAChR agonist-1 (compound 10a) is a potent M4 mAChR agonist with an EC50 >10 μM for human M4 .
    M4 mAChR agonist-1
  • HY-176976

    Drug-Linker Conjugates for ADC Cancer
    Exatecan-mpGNNG (Compound 10a) is the linker-payload component of an antibody-drug conjugate (ADC). Exatecan-mpGNNG is composed of Exatecan (HY-13631), a potent topoisomerase I inhibitor, and the linker .
    Exatecan-mpGNNG
  • HY-127024A

    Thyroid Hormone Receptor Metabolic Disease
    TR antagonist 2 (Compound 10a) is a competitive thyroid hormone receptors (TRα/β) antagonist (IC50=47 nM). TR antagonist 2 competes with triiodothyronine (T3) for binding to the ligand-binding domain of TR to block receptor-coactivator complex formation and inhibit target gene transcription, reducing thyroid hormone-mediated hypermetabolic effects. TR antagonist 2 is promising for research of hyperthyroidism (e.g., Graves' disease) and thyrotoxicosis .
    TR antagonist 2
  • HY-135848

    Phosphodiesterase (PDE) Cancer
    N-Methylbenzamide is a potent phosphodiesterase 10A (PDE10A) inhibitor. N-Methylbenzamide has anti-cancer activity .
    N-Methylbenzamide
  • HY-18078

    Phosphodiesterase (PDE) Neurological Disease
    PQ-10 is a potent inhibitor of Phosphodiesterase 10A (PDE10A) with IC50 andED50 of 4.6 nM and 13 mg/kg, respectively. PQ-10 induces patterns of brain glucose metabolism which can be a potential translational biomarker. PQ-10 has the potential for researching psychiatric disorders like schizophrenia .
    PQ-10
  • HY-117604
    THPP-1
    1 Publications Verification

    Phosphodiesterase (PDE) Neurological Disease
    THPP-1, a SGC chemical probe, is a potent and orally bioavailable phosphodiesterase 10A (PDE10A) inhibitor, with Ki values of 1 nM and 1.3 nM for human and rat PDE10A, respectively. THPP-1 has excellent pharmacokinetic properties in preclinical species .
    THPP-1
  • HY-151959

    FXR Cardiovascular Disease Metabolic Disease Inflammation/Immunology
    FXR agonist 4 (compound 10a) is an agonist of farnesoid X receptor (FXR) with an EC50 value of 1.05 μM. FXR agonist 4 effectively improves hyperlipidemia, hepatic steatosis, insulin resistance and hepatic inflammation in DIO mice. FXR agonist 4 can be used for the research of non-alcoholic fatty liver disease (NAFLD) .
    FXR agonist 4
  • HY-RI00059

    MicroRNA Cancer
    hsa-miR-10a-5p inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
    hsa-miR-10a-5p inhibitor
    hsa-miR-10a-5p inhibitor
  • HY-12913

    Phosphodiesterase (PDE) Neurological Disease
    AMG 579 is a potent, selective, and efficacious inhibitor of phosphodiesterase 10A (PDE10A) with an IC50 of 0.1 nM.
    AMG 579
  • HY-152838

    RO554965

    Phosphodiesterase (PDE) Neurological Disease
    Gemlapodect (RO554965) is an inhibitor of phosphodiesterase 10A (PDE10A). Gemlapodect can be used for researching schizophrenia .
    Gemlapodect
  • HY-148954

    Adenosine Receptor Phosphodiesterase (PDE) Cancer
    PBF-999 is a phosphodiesterase10A (PDE-10A) and adenosine A2A receptor (A2AR) dual antagonist.
    PBF-999
  • HY-153168

    Phosphodiesterase (PDE) Cardiovascular Disease
    Bemoradan (compound 10a) is an orally active and selective canine Phosphodiesterase (PDE) fraction III inhibitor. Bemoradan is a long-acting, potent, inotropic vasodilator and a novel cardiotonic agent, and can be used in congestive heart failure research .
    Bemoradan
  • HY-149431

    HSP Potassium Channel Cancer
    NDNA4 (compound 17) is a selective inhibitor of Hsp90α (IC50: 0.34 μM). NDNA4 is a permanently charged analog with low membrane permeability and low cytotoxicity against Ovcar-8 and MCF-10A ((IC50 >100 μM)). NDNA4 prevents disruption of hERG channel maturation without generating a heat shock response or causing degradation of Hsp90α-dependent client proteins .
    NDNA4
  • HY-RS18435

    Small Interfering RNA (siRNA) Others

    Clec10a Mouse Pre-designed siRNA Set A contains three designed siRNAs for Clec10a gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Clec10a Mouse Pre-designed siRNA Set A
    Clec10a Mouse Pre-designed siRNA Set A
  • HY-RS15828

    Small Interfering RNA (siRNA) Others

    WNT10A Human Pre-designed siRNA Set A contains three designed siRNAs for WNT10A gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    WNT10A Human Pre-designed siRNA Set A
    WNT10A Human Pre-designed siRNA Set A
  • HY-178987

    Mitochondrial Metabolism Phosphodiesterase (PDE) Cancer
    BJH-86 is a soluble mitochondrial complex 1 inhibitor (oxygen consumption rate inhibition IC50 = 5 μM). BJH-86 exhibits weak inhibitory activity against phosphodiesterase 10A (PDE10A) (IC50 >10 μM). BJH-86 can reduce cellular oxygen consumption and inhibit cancer cell proliferation. BJH-86 can be used for the research of cancer, such as lung cancer .
    BJH-86
  • HY-178440

    EGFR COX Apoptosis Inflammation/Immunology Cancer
    EGFR/COX-2-IN-2 (Compound 10a) is a dual inhibitor targeting epidermal growth factor receptor (EGFR) (IC50= 6.0 μM) and cyclooxygenase-2 (COX-2) (IC50=50 μM). EGFR/COX-2-IN-2 induces S-phase cell cycle arrest and apoptosis. EGFR/COX-2-IN-2 is promising for research of cancers and inflammation-related diseases .
    EGFR/COX-2-IN-2
  • HY-178951

    STING IKK Reactive Oxygen Species (ROS) IFNAR PARP Caspase Inflammation/Immunology
    STING-IN-17 (compound 10a) is an orally active STING (human STING IC50 = 29 nM, mouse STING IC50 = 15 nM) inhibitor. STING-IN-17 can inhibit the phosphorylation of STING, TBK1 and IRF3. STING-IN-17 dose dependently inhibits the mRNA expression of IP10, IFNB1 and ISG56. STING-IN-17 can reduce ROS and inhibit the expression of cleaved-PARP/caspase-3. STING-IN-17 can improve kidney function. STING-IN-17 can be used for research on inflammatory conditions such as acute kidney injury .
    STING-IN-17
  • HY-E70897

    Biochemical Assay Reagents Metabolic Disease
    Xylanase 10A, Cellvibrio japonicus (EC 3.2.1.8) is the name given to a class of enzymes which degrade the linear polysaccharide beta-1,4-xylan into xylose, thus breaking down hemicellulose, one of the major components of plant cell walls.
    Xylanase 10A, Cellvibrio japonicus
  • HY-123743

    Phosphodiesterase (PDE) Neurological Disease
    JNJ-42314415 is a centrally active phosphodiesterase 10A (PDE10A) inhibitor, with Ki values of 35 nM and 64 nM for human recombinant PDE10A and rPDE10A, respectively .
    JNJ-42314415
  • HY-158237

    Phosphodiesterase (PDE) Neurological Disease
    PDE10A-IN-3 (Compound 8a) is an inhibitor of phosphodiesterase 10A (PDE10A). PDE10A-IN-3 can be used in schizophrenia research .
    PDE10A-IN-3
  • HY-R00058

    MicroRNA Cancer
    hsa-miR-10a-3p mimics are small, chemically synthesized double-stranded RNAs that mimic endogenous miRNAs and enable miRNA functional analysis by up-regulation of miRNA activity.
    hsa-miR-10a-3p mimic
    hsa-miR-10a-3p mimic
  • HY-160111

    Phosphodiesterase (PDE) Neurological Disease
    PDM-042 is a potent, selective, and orally active phosphodiesterase 10A (PDE10A) inhibitor. PDM-042 shows potent inhibitory activities for human and rat PDE10A with IC50 values of less than 1 nM and more than 1000-fold selectivity against other phosphodiesterases. PDM-042 can be used for the research of schizophrenia .
    PDM-042
  • HY-128349

    Phosphodiesterase (PDE) Neurological Disease
    MT-3014 is a potent, highly selective and brain-penetrated phosphodiesterase 10A (PDE 10A) inhibitor, with IC50s of 0.062 nM and 0.09 nM for human PDE 10A and bovine PDE 10A, respectively .
    MT-3014
  • HY-P99619

    SCT-I10A

    PD-1/PD-L1 Cancer
    Finotonlimab (SCT-I10A) is a recombinant humanised IgG PD-1 antibody. Finotonlimab has the potential for solid tumors or lymphomas research .
    Finotonlimab
  • HY-P991111

    Transmembrane Glycoprotein Inflammation/Immunology
    Anti-Mouse TIGIT Antibody (10A7) is a mouse IgG2 monoclonal antibody that targets TIGIT. Recommend Isotype Controls: Mouse IgG2a kappa, Isotype Control (HY-P99978).
    Anti-Mouse TIGIT Antibody (10A7)
  • HY-131973

    Phosphodiesterase (PDE) Cardiovascular Disease Metabolic Disease
    PDE10A-IN-2 hydrochloride is a potent, highly selective and orally active phosphodiesterase 10A (PDE10A) inhibitor with an IC50 of 2.8 nM. PDE10A-IN-2 hydrochloride shows selectivity of >3500-fold against other PDE subtypes. PDE10A-IN-2 hydrochloride can be used for pulmonary arterial hypertension (PAH) research .
    PDE10A-IN-2 hydrochloride
  • HY-174499

    mRNA Others
    Cas9 Nickase D10A mRNA expresses a version of the Streptococcus pyogenes SF370 Cas9 protein (CRISPR Associated Protein 9) that contains a D10A amino acid substitution. This mRNA also contains a C-terminal nuclear localization signal followed by a HA tag.Cas9 functions as part of the CRISPR (clustered regularly interspaced short palindromic repeats) genome editing system. In the CRISPR system, an RNA guide sequence targets the site of interest and the Cas9 protein is employed to perform the DNA cleavage. While wild-type Cas9 creates a double-stranded break at the target site, Cas9 nickase creates a single-stranded break. This favors homology-directed repair and decreases the occurrence of non-homologous end joining.
    Cas9 Nickase D10A mRNA (5moU)
  • HY-173360

    Phosphodiesterase (PDE) Cardiovascular Disease
    PDE10A-IN-5 (Compound A30) is an inhibitor of phosphodiesterase 10A (PDE10A) with oral activity, and its IC50 value is 3.5 nM. PDE10A-IN-5 exerts the activity of inhibiting pulmonary vascular remodeling by inhibiting PDE10A and activating the cyclic adenosine monophosphate (cAMP)-associated signaling pathway, and can be used for research in the field of pulmonary arterial hypertension .
    PDE10A-IN-5
  • HY-166876S

    Isotope-Labeled Compounds Others
    Nicergoline impurity 18-d4 is deuterium labeled ((6aR,9R,10aS)-10a-Methoxy-7-methyl-4,6,6a,7,8,9,10,10a-octahydroindolo[4,3-fg]quinolin-9-yl)methanol (Nicergoline Impurity) .
    Nicergoline impurity 18-d4
  • HY-168064

    EGFR Cancer
    EGFR-IN-124 (compound 10A) is an EGFR inhibitor, with IC50 of 0.54 μM. EGFR-IN-124 can be used in anti-cancer research .
    EGFR-IN-124
  • HY-RI00058A

    MicroRNA Cancer
    hsa-miR-10a-3p antagomirs are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA antagomirs have 2 phosphorothioates at the 5' end, 4 phosphorothioates at the 3' end, 1 cholesterol group at the 3' end, and full-length nucleotide 2'-methoxy modification. The miRNA antagomirs strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning. Stability of miRNA antagomirs appears to be significantly higher than miRNA inhibitors, they exhibits enhanced cellular uptake, stability and regulatory activity in vivo.
    hsa-miR-10a-3p antagomir
    hsa-miR-10a-3p antagomir
  • HY-146652

    Bacterial Infection
    UGM-IN-3 (compound 10a) is a UDP-galactopyranose mutase (UGM) inhibitor with a Kd of 66 μM. UGM-IN-3 inhibits the growth of Mycobacterium tuberculosis with a MIC value of 6.2 μg/mL .
    UGM-IN-3
  • HY-117838

    Phosphodiesterase (PDE) Neurological Disease
    Phosphodiesterase 10-IN-2 (THPP-4) is an oral active phosphodiesterase 10A (PDE10A) inhibitor with the Ki of 4.5 nM. Phosphodiesterase 10-IN-2 can be used for study of schizophrenia .
    Phosphodiesterase 10-IN-2
  • HY-18037

    Phosphodiesterase (PDE) Others
    AMG-7980 exhibits high affinity to phosphodiesterase 10A (PDE10A), with a KD of 0.94 nM. AMG-7980 can be used as a tracer of PDE10A, when labeled with radioactive isotope .
    AMG-7980
  • HY-N10922

    Others Cancer
    (3S,4aS,10aS)-3-(Acetyloxy)-2,3,4,4a,10,10a-hexahydro-6-hydroxy-1,1,4a-trimethyl-7-(1-methylethyl)-9(1H)-phenanthrenone (compound 3), a Palmitate, can be isolated from the root tissue of Salvia miltiorrhiza. (3S,4aS,10aS)-3-(Acetyloxy)-2,3,4,4a,10,10a-hexahydro-6-hydroxy-1,1,4a-trimethyl-7-(1-methylethyl)-9(1H)-phenanthrenone (compound 3) shows anti-cancer activity against human cancer cell lines with DC50s of 25.5 μg/mL (HeLa), 37.5 μg/mL (HepG2), 30.2 μg/mL (OVCAR-3), respectively .
    (3S,4aS,10aS)-3-(Acetyloxy)-2,3,4,4a,10,10a-hexahydro-6-hydroxy-1,1,4a-trimethyl-7-(1-methylethyl)-9(1H)-phenanthrenone
  • HY-139035

    CRFR Neurological Disease
    CRHR1 antagonist 1 (compound 10a) is a non-peptide corticotropin-releasing hormone type 1 receptor (CRHR1) antagonist. CRHR1 antagonist 1 can be utilized in mental disorders research .
    CRHR1 antagonist 1
  • HY-162758

    Aldose Reductase Metabolic Disease
    ALR2-IN-5 (Compound 10a) is an inhibitor of ALR2 with an IC50 value of 99.29 nM. ALR2-IN-5 exhibits hypoglycemic effects and can be utilized in research related to diabetes .
    ALR2-IN-5
  • HY-155185A

    iGluR Neurological Disease
    NMDA receptor antagonist 8 (Compound (R)-10a) is GluN2B subunit-selective NMDA Receptor antagonist, with an Ki of 265 nM and an IC50 of 62 nM. NMDA receptor antagonist 8 can be used for research of neurodegenerative diseases .
    NMDA receptor antagonist 8
  • HY-155185

    iGluR Neurological Disease
    NMDA receptor antagonist 7 (Compound (S)-10a) is GluN2B subunit-selective NMDA Receptor antagonist, with an Ki of 93 nM and an IC50 of 72 nM. NMDA receptor antagonist 7 can be used for research of neurodegenerative diseases .
    NMDA receptor antagonist 7
  • HY-10030

    PF-2545920 succinate

    Phosphodiesterase (PDE) Neurological Disease
    Mardepodect succinate (PF-2545920 succinate) is a potent and specific phosphodiesterase 10A (PDE10A) inhibitor with potential activity in the treatment of schizophrenia. Mardepodect succinate has been further optimized to improve brain penetration and compound-like properties for use in schizophrenia research .
    Mardepodect succinate
  • HY-131194

    Interleukin Related Cancer
    JAK2/STAT3-IN-1 (compound (S)-10a) is a potent GP130 inhibitor with an IC50 of 3.04 µM. JAK2/STAT3-IN-1 shows anti-tumor activity .
    JAK2/STAT3-IN-1
  • HY-172407

    Opioid Receptor Others
    KOR agonist 5 (Compound 10a) is a KOR/MOR modulator with agonistic activity towards KOR and antagonistic activity towards MOR. KOR agonist 5 can effectively block morphine-induced antinociception and inhibition of intestinal motility. KOR agonist 5 can be used in the research of Substance Use Disorder (SUD) .
    KOR agonist 5
  • HY-161663

    Phosphodiesterase (PDE) Cardiovascular Disease
    Phosphodiesterase-IN-2 (Compound C7) is a selective, orally active inhibitor for phosphodiesterase 10A (PDE10A), with an IC50 of 11.9 nM. Phosphodiesterase-IN-2 improves the stability of liver microsomes, and lowers BBB permeability. Phosphodiesterase-IN-2 exhibits good pharmacokinetic characters, and attenuates isoprenaline (HY-108353)-induced cardiac hypertrophic in mouse models .
    Phosphodiesterase-IN-2
  • HY-119467

    Ser/Thr Protease Cancer
    MDK0734 is a selective inhibitor that inhibits feline hepsin B endopeptidase and exopeptidase activities. MDK0734 demonstrated efficacy in a cell-based in vitro tumor invasion model, significantly attenuating the invasive ability of MCF-10A neoT cells. MDK0734 provides new potential inhibitors for the development of clinically useful compounds targeting the deleterious effects of feline hepsin B in cancer progression .
    MDK0734
  • HY-159515

    Apoptosis DNA/RNA Synthesis Reactive Oxygen Species (ROS) Cancer
    PBE-AMF is a prodrug that activates H2O2 with anticancer activity. PBE-AMF impedes tumor proliferation by inhibiting DNA synthesis, reducing ATP levels, inducing apoptosis, and arresting the cell cycle. PBE-AMF potently and selectively inhibits the proliferation of MDA-MB-231 cells (IC50=6.4 μM) while sparing non-cancerous MCF-10A cells .
    PBE-AMF
  • HY-116264

    Ser/Thr Protease Cancer
    CatB-IN-1 is an enzyme inhibitor with significant inhibitory activity against tumor invasion. CatB-IN-1 may reduce the invasiveness of tumor cells by regulating intracellular protein metabolism. CatB-IN-1 demonstrates effective anti-invasive ability in cell models and can significantly reduce the invasive ability of MCF-10A neoT cells. The structure-activity relationship study of CatB-IN-1 shows that its design can target multiple functions of cat hepsin B .
    CatB-IN-1

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: